Vikki L Conway Form 3 TEVA PHARMACEUTICAL INDUSTRIES / Vikki L Conway ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Conway Vikki L

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/25/2023

3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See "Remarks"

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	⁽¹⁾	03/12/2024	Ordinary Shares⁽²⁾	2,268	48.76	D
Stock Options (right to buy)	⁽³⁾	03/12/2025	Ordinary Shares⁽²⁾	3,504	60.21	D
Stock Options (right to buy)	⁽⁴⁾	03/17/2026	Ordinary Shares⁽²⁾	8,003	53.5	D
Stock Options (right to buy)	⁽⁵⁾	03/03/2027	Ordinary Shares⁽²⁾	15,003	34.7	D
Stock Options (right to buy)	⁽⁶⁾	09/18/2027	Ordinary Shares⁽²⁾	4,571	16.99	D
Stock Options (right to buy)	⁽⁷⁾	03/02/2028	Ordinary Shares⁽²⁾	25,003	19.16	D
Restricted Share Units	⁽⁸⁾	⁽⁸⁾	Ordinary Shares⁽²⁾	4,294	⁽⁹⁾	D
Restricted Share Units	⁽¹⁰⁾	⁽¹⁰⁾	Ordinary Shares⁽²⁾	9,911	⁽⁹⁾	D
Restricted Share Units	⁽¹¹⁾	⁽¹¹⁾	Ordinary Shares⁽²⁾	21,354	⁽⁹⁾	D
Restricted Share Units	⁽¹²⁾	⁽¹²⁾	Ordinary Shares⁽²⁾	20,717	⁽⁹⁾	D

Explanation of Responses:

1. Stock options were granted on March 12, 2014, with 1,134 having vested on each of March 12, 2016 and March 12, 2017.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

3. Stock options were granted on March 12, 2015, with 876 having vested on each of March 12, 2016, March 12, 2017, March 12, 2018, and March 12, 2019.

4. Stock options were granted on March 17, 2016, with 2,000 having vested on each of March 17, 2017, March 17, 2018 and March 12, 2019, and 2,003 having vested on March 17, 2020.

5. Stock options were granted on March 3, 2017, with 3,750 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 3,753 having vested on March 3, 2021.

6. Stock options were granted on September 18, 2017, with 4,571 having vested on September 18, 2019.

7. Stock options were granted on March 2, 2018, with 6,250 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021, and 6,253 having vested on March 2, 2022.

8. Restricted share units were granted on February 28, 2020, with 4,294 vesting on February 28, 2024.

9. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

10. Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025.

11. Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.

12. Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

Remarks:

Exhibit 24 - Power of Attorney. Acting Head of Global Human Resources.

	/s/ Dov Bergwerk, as attorney-in-fact for Vikki L. Conway	10/05/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Vikki L Conway Form 3TEVA PHARMACEUTICAL INDUSTRIES / Vikki L Conway ownership change